Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
8,801 received a placebo
Retatrutide (LY-3437943) is an investigational drug developed by Eli Lilly that acts as a triple hormone receptor agonist : GLP-1 (glucagon-like peptide-1) receptor agonist GIP (glucose-dependent insulinotropic polypeptide) receptor agonist Glucagon receptor agonist - read about why this is so important here This triagonist approach amplifies the metabolic impact seen with GLP-1 and GIP combinations like tirzepatide, while also leveraging glucagons thermogenic and energy-expending properties
Some of the negative microbial signatures for GLP-1 RA treatment in T2D patients might be related to diseases
Discover the latest trends, expert tips, delicious recipes, and inspiring stories as we embark on the journey to optimal health together
US$ 26.47
US$ 23.33
US$ 25.43
US$ 21.50
US$ 19.98
